Radiopharm Theranostics Ltd
Research Radiopharm Theranostics Ltd (RAD) on Bullrun: market cap AUD 43.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRAD
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 43.38M
- Financial periodFY2025
- RevenueAUD 3.63M
- Revenue growth1114.3%
- Net income-AUD 38.34M
- Free cash flow-AUD 36.65M
- Gross margin1.1%
Valuation Snapshot
latest market cap is AUD 43.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 3.63M | -AUD 38.34M | -AUD 36.65M | 1.1% | -0.02 | AUD 29.12M | n/a | AUD 44.79M |
| FY2024 | AUD 299.23K | -AUD 47.95M | -AUD 22.98M | 100.0% | -0.12 | AUD 18.58M | n/a | AUD 28.12M |
| FY2023 | AUD 292.36K | -AUD 34.61M | -AUD 24.73M | 100.0% | -0.11 | AUD 11.70M | n/a | AUD 44.38M |
| FY2022 | AUD 8.83K | -AUD 30.34M | -AUD 38.25M | 100.0% | -0.15 | AUD 26.98M | n/a | AUD 62.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 43.38M | n/a | n/a | n/a |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Radiopharm Theranostics Ltd's market cap?
Radiopharm Theranostics Ltd's market capitalization is AUD 43.38M.
What does Radiopharm Theranostics Ltd do?
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.